Dear members and partners,

You have before you the first edition of EMSP's Membership Newsletter, a collaborative publication made possible by the great support of MS societies across Europe. 

The eight articles you will read are focused on access to MS treatment and related topics.  

Contributions range from informative overviews to strong testimonies. They are all terrific examples of dedicated MS advocacy. 

We believe this newsletter can truly reflect the power of MS voices coming together. But we need your help to make this belief a certainty.

Just read and disseminate the newsletter. Then tell us your thoughts. We will listen! 

Read more [on page 2 of the linked pdf version].

Source: Under Pressure project (
MS treatment: statistics and challenges 
The total number of people on treatment is currently 2,351. At national level there are between 5,000 and 7,000 people living with MS.
The treatment of multiple sclerosis in Bulgaria has two main aspects - immunomodulatory therapy and symptomatic treatment.

Read more [on page 3 of the linked pdf version].
The 'rocky road' to prescription and reimbursement 
The MS Society of Ireland writes about the often complicated process behind prescription and reimbursement of new MS treatments for people living with MS in the country. 

The related drugs are fampridine, natalizumab and alemtuzumab. 

Read more [on page 6].
MS testimony:
Living with disease progression 
I am 31 years old and I was diagnosed with MS in 2007.

At the beginning I had no idea what “multiple sclerosis” meant and I wasn’t aware of its consequences. 

Learning to live with MS took great effort and sacrifice. 

Read more [on page 9].
United Kingdom
Is access to MS treatment still a lottery?  

Earlier this year the UK MS Society carried out a new My MS, My Needs survey building on the first such research from 2012-2013. 

More than 11,000 people with MS responded in 2016.

Both positive and negative developments were reported. 

Read more [on page 12].
Neurologist talks about MS pain  
A study commissioned in early 2016 by the Danish MS Society showed that severe pain affects 14 percent of respondents every day, while 32 percent experience moderate pain. 

The Society interviewed a specialist on the topic and then decided to translate the resulting article for the benefit of the wider MS community in Europe. 

Read more [on page 4 of the linked pdf version].
Overcoming treatment challenges   
Access to MS treatment in Poland has never been straightforward, and drugs reimbursed through the national healthcare system have always been difficult to obtain. 

But there was marked progress in recent years through sustained advocacy campaigns. More remains to be done. 

Read more [on page 7].
MS registry:
Addressing key healthcare questions  
The healthcare standard in Switzerland is generally very high and access to related services is guaranteed. But there is an overall lack of comprehensive statistical data. 

The recent launch of the Swiss Multiple Sclerosis Registry is a big step towards tackling such problems.

Read more [on page 11].
MS testimony:
Access to treatment, a matter of luck   
I consider myself a lucky person.

I am lucky to have caught my MS early and to have received treatment within two months from my diagnosis. I had no MRI modification in four years. 

If you were living in Romania, you would understand just how much this means. 

Read more [on page 13].
Copyright © EMSP 2016
All rights reserved

Contact us:

Want to stop receiving these emails?
You can unsubscribe from this list


This email was sent to
why did I get this?    unsubscribe from this list    update subscription preferences
EMSP · Rue Auguste Lambiotte 144 / 8 · Brussels 1030 · Belgium

Email Marketing Powered by Mailchimp